| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS44029378 | HTLV-1 | ENSG00000116678.20 | protein_coding | LEPR | No | No | 3953 | P48357 Q4G138 |
| TVIS44037077 | HTLV-1 | ENSG00000116678.20 | protein_coding | LEPR | No | No | 3953 | P48357 Q4G138 |
| TVIS44037316 | HTLV-1 | ENSG00000116678.20 | protein_coding | LEPR | No | No | 3953 | P48357 Q4G138 |
| TVIS44037315 | HTLV-1 | ENSG00000116678.20 | protein_coding | LEPR | No | No | 3953 | P48357 Q4G138 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | LEPR |
|---|---|
| DrugBank ID | DB09046 |
| Drug Name | Metreleptin |
| Target ID | BE0003376 |
| UniProt ID | P48357 |
| Regulation Type | agonist |
| PubMed IDs | 25249580 |
| Citations | Moon HS, Huh JY, Dincer F, Schneider BE, Hasselgren PO, Mantzoros CS: Identification and saturable nature of signaling pathways induced by metreleptin in humans: comparative evaluation of in vivo, ex vivo, and in vitro administration. Diabetes. 2015 Mar;64(3):828-39. doi: 10.2337/db14-0625. Epub 2014 Sep 23. |
| Groups | Approved |
| Direct Classification | Peptides |
| SMILES | |
| Pathways | |
| PharmGKB | |
| ChEMBL | CHEMBL2107857 |
